Dr. Stuart E. Pollack Will Focus on Cases in the Pharmaceutical Sector
(New York) – LawFuel.com – Legal Newswire Service – DLA Piper announced today that Stuart E. Pollack has joined the New York office as a partner, and will work with the firm’s market-leading patent litigation and pharmaceutical practices.
Dr. Pollack’s practice focuses primarily on patent litigation. He has vast experience litigating patent cases in the pharmaceutical sector, where he has a long track record of outstanding trial work for some of the industry’s best-known companies.
“Stuart’s arrival meaningfully enhances our patent litigation practice, and he adds significant capabilities to our pharmaceutical practice,” said John Allcock, Global Co-Chair of DLA Piper’s Intellectual Property and Technology group. “Stuart helps us fulfill our strategic goals for the patent litigation and pharmaceutical practices, the New York office and our global Intellectual Property and Technology group.”
“DLA Piper already has a market-leading pharmaceutical litigation practice, and Stuart brings significant new capabilities in New York that strengthen our offering to clients,” said John Dougherty, Co-Chair of DLA Piper’s Patent Litigation practice and member of the firm’s pharmaceutical practice. “Stuart is a great lawyer who has earned a well-deserved reputation representing branded companies in Hatch-Waxman litigation. We look forward to having him on the team.”
About Stuart Pollack
Dr. Pollack has extensive trial experience in federal court and has helped obtain favorable judgments in several suits on behalf of pioneer drug companies, including suits brought under the Hatch-Waxman Act against potential generic entrants. His work has focused on pharmaceutical products and drug substances, polymers, optics, and chemical reactors, and he has also worked on cases involving mechanical inventions. He has substantial experience in patent opinion and patent prosecution work, and he has successfully represented companies in suits at the International Trade Commission. He has also helped obtain patents for his pharmaceutical and chemical technology clients at the Patent and Trademark Office. Dr. Pollack comes to DLA Piper from Patterson Belknap Webb & Tyler LLP, where he was a partner in the Litigation and IP Litigation groups.
Pollack received his J.D. from Columbia Law School, where he was a Kent Scholar. He also has a Ph.D. from Northwestern University in Physical Chemistry, specializing in metallic systems, including metal clusters. Prior to that he earned an M.S. from Northwestern and a B.A. from the University of Rochester in Chemistry.
About DLA Piper
DLA Piper has 3,500 lawyers in 29 countries and 67 offices throughout the US, UK, Continental Europe, Middle East and Asia. In certain jurisdictions, this information may be considered attorney advertising.
Jason Costa, Media Relations, DLA Piper, 212.776.3739